NCT04401761View on ClinicalTrials.gov

A Study to Collect Data on the Treatment Pattern of Xarelto + Acetylsalicylic Acid in the Routine Clinical Practice in Patients Who Are Suffering From a Condition That Narrows the Blood Vessels Supplying the Heart and / or a Condition That Most Commonly Narrows the Blood Vessel in the Legs

CompletedOBSERVATIONAL
Enrollment

3,189

Participants

Timeline

Start Date

May 28, 2020

Primary Completion Date

June 30, 2023

Study Completion Date

September 29, 2023

Conditions
Coronary Artery DiseasePeripheral Artery Disease
Interventions
DRUG

Rivaroxaban (BAY59-7939, Xarelto)

2.5 mg twice daily

DRUG

Acetylsalicylic acid

75 - 100 mg once daily at the discretion of the investigator

Trial Locations (10)

Unknown

Many Locations, Multiple Locations

Many Locations, Multiple Locations

Many Locations, Multiple Locations

Many Locations, Multiple Locations

Many Locations, Multiple Locations

Many Locations, Multiple Locations

Many Locations, Multiple Locations

Many Locations, Multiple Locations

Many Locations, Multiple Locations

Many Locations, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT04401761 - A Study to Collect Data on the Treatment Pattern of Xarelto + Acetylsalicylic Acid in the Routine Clinical Practice in Patients Who Are Suffering From a Condition That Narrows the Blood Vessels Supplying the Heart and / or a Condition That Most Commonly Narrows the Blood Vessel in the Legs | Biotech Hunter | Biotech Hunter